Integra LifeSciences Holdings Corporation (IART) Balance Sheet

The decline in total assets and equity over the past ten quarters suggests the company has been absorbing significant charges, likely related to impairments and operational losses. The reduction in equity from $1.6B to $1.1B, a 31% decline, indicates that retained earnings have been heavily depleted, consistent with the cumulative net losses reported in the income statement. This trajectory implies that the balance sheet is weakening, and the company may have limited capacity to absorb further shocks without additional external financing.

While total debt has remained constant at $2.0B, the equity base has contracted, causing the D/E ratio to climb from 1.28 to 1.94. This indicates that the company is becoming more leveraged relative to its shrinking equity cushion. The elevated leverage, combined with negative net margins, suggests that debt service may consume a significant portion of operating cash flow, and refinancing risk could emerge if credit conditions tighten. Investors should monitor covenant compliance and the company's ability to generate sufficient cash flow to service this debt.

The substantial write-down of goodwill from $1.1B to $613.2M indicates that the company has recognized significant impairments, likely related to acquisitions that have underperformed. This reduces the asset base and signals that the company may have overpaid for past acquisitions. The remaining goodwill still represents a sizable portion of total assets, and further impairments could occur if the business does not recover. The PPE net has increased modestly from $497.2M to $584.1M, suggesting continued investment in fixed assets, possibly for remediation efforts, but the overall asset mix is shifting toward a lower proportion of intangibles.

The sharp decline in retained earnings from $943.6M to $427.2M indicates that the company has been generating significant net losses, which have directly reduced equity. This erosion is consistent with the negative net margins reported in the income statement. The equity base is now only $1.1B, and with a D/E of 1.94, the company has limited financial flexibility. The lack of dividends and negligible buybacks, as noted in the cash flow analysis, suggests that management is preserving cash to service debt and fund operations, but the equity cushion is thinning.

The current ratio has improved significantly from 1.23 in Q2 2025 to 3.40 in Q2 2026, suggesting that current assets are ample to cover short-term liabilities. However, cash has declined from $591.9M in Q1 2024 to $214.4M, indicating that the company has been using cash to fund operations and debt service. The improvement in the current ratio may be driven by an increase in receivables or inventory, which could be less liquid than cash. Given the ongoing operational challenges and negative cash flow trends, the cash buffer appears thin, and the company may need to rely on credit facilities if cash generation does not improve.